AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8406063 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 73
Study 8406063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% sezolamide
Number of subjects: 73
Study 8406063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 3512622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene (23 mg/week for men, 13 mg/week for women)
Number of subjects: 40
Study 3512622 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 40
Study 30131313 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey with acceptance-facilitating intervention (AFI)
Number of subjects: 489
Study 30131313 — intervention group
Group type: COMPARATOR
Intervention: Web-based survey without acceptance-facilitating intervention (AFI)
Number of subjects: 489
Study 27585532 — intervention group
Group type: EXPERIMENTAL
Intervention: early goal-directed nutrition
Number of subjects: 200
Study 27585532 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 200
Study 24335446 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during brain death evaluation
Number of subjects: 58
Study 24335446 — intervention group
Group type: COMPARATOR
Intervention: Not present during brain death evaluation (control)
Number of subjects: 58
Study 24335446 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence (intervention)
Number of subjects: 58
Study 24335446 — intervention group
Group type: COMPARATOR
Intervention: Not present (control)
Number of subjects: 58
Study 22575036 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 phosphatidylserine (PS)
Number of subjects: 60
Study 22575036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20051119 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk tailored intervention including educational intervention and counselling based on risk group assignment.
Number of subjects: 600
Study 20051119 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual in primary care.
Number of subjects: 600
Study 18978566 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 230 mg/m followed by cisplatin 75 mg/m on day 1 every 21 days, with granulocyte colony stimulating factor 5 microg/kg/d beginning on day 3 of each cycle
Number of subjects: 34
Study 16343372 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0
Study 16343372 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) combined with other interventions
Number of subjects: 0
Study 12436430 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic therapy (DLT) with adjunctive intermittent pneumatic compression (IPC)
Number of subjects: 50
Study 12436430 — intervention group
Group type: COMPARATOR
Intervention: Decongestive lymphatic therapy (DLT) alone
Number of subjects: 50
Study 11874940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11874940 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg pioglitazone
Number of subjects: 58
Study 11874940 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pioglitazone
Number of subjects: 58
Study 11874940 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 58
Study 11874940 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg pioglitazone
Number of subjects: 58
Study 9521337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate (vitamin C)
Number of subjects: 20
Study 9521337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7708954 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fractionation at 40 Gy
Number of subjects: 32
Study 7708954 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fractionation at 50 Gy
Number of subjects: 32
Study 7708954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Number of subjects: 32
Study 7708954 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 32
Study 7708954 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation
Number of subjects: 32
Study 2691013 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms subcutaneously 15 min before glucose intake)
Number of subjects: 8
Study 2691013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2691013 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995
Number of subjects: 8
Study 29952675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) 10 min at 10°C, n=10
Number of subjects: 23
Study 29952675 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery control (CON), n=13
Number of subjects: 23
Study 28318550 — intervention group
Group type: COMPARATOR
Intervention: Circular stapling
Number of subjects: 100
Study 28318550 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangulating stapling
Number of subjects: 100
Study 26618470 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxylapatite (CaHA) treatment
Number of subjects: 30
Study 26618470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment until end of study)
Number of subjects: 30
Study 23551070 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin (OXT)
Number of subjects: 47
Study 23551070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 47
Study 21495524 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual (SPIRIT) intervention
Number of subjects: 100
Study 21495524 — intervention group
Group type: COMPARATOR
Intervention: Educational (EDUC) intervention
Number of subjects: 100
Study 18339449 — intervention group
Group type: EXPERIMENTAL
Intervention: ED observation unit care
Number of subjects: 153
Study 18339449 — intervention group
Group type: COMPARATOR
Intervention: Routine inpatient care
Number of subjects: 153
Study 16826364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400-1,200 IU per day) with calcium (800-1,500 mg per day)
Number of subjects: 10000
Study 16826364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 12627044 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 5 mg/day for 14 days (days 12-25)
Number of subjects: 241
Study 12627044 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 mg/day for 14 days (days 12-25)
Number of subjects: 241
Study 12627044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone, 20 mg/day for 14 days (days 12-25)
Number of subjects: 241
Study 12627044 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women (group Y)
Number of subjects: 241
Study 10615885 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI alone
Number of subjects: 258
Study 10615885 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI after mild ovarian hyperstimulation
Number of subjects: 258
Study 10615885 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 258
Study 10615885 — intervention group
Group type: COMPARATOR
Intervention: IUI groups (both IUI alone and IUI after mild ovarian hyperstimulation)
Number of subjects: 258
Study 10615885 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI
Number of subjects: 258
Study 9174314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 20 microg/h
Number of subjects: 90
Study 9174314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 10 microg/h
Number of subjects: 90
Study 9174314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 15 microg/h
Number of subjects: 90
Study 9174314 — intervention group
Group type: COMPARATOR
Intervention: Control group (bupivacaine and fentanyl)
Number of subjects: 90
Study 8239616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mefloquine (25 mg/kg)
Number of subjects: 139
Study 8239616 — intervention group
Group type: COMPARATOR
Intervention: Conventional mefloquine (15 mg/kg)
Number of subjects: 139
Study 29500116 — intervention group
Group type: EXPERIMENTAL
Intervention: Asset-based practices (intervention focusing on existing behavior)
Number of subjects: 0
Study 29500116 — intervention group
Group type: COMPARATOR
Intervention: Needs-based practices (intervention focusing on acquiring missing skills)
Number of subjects: 0
Study 26572896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 61
Study 26572896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 61
Study 26572896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24746163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype confirmation concerns
Number of subjects: 94
Study 22961024 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disinfection of high-touch surfaces
Number of subjects: 0
Study 21041348 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (online multifamily psychoeducational therapy)
Number of subjects: 55
Study 21041348 — intervention group
Group type: COMPARATOR
Intervention: Usual care (treatment as usual)
Number of subjects: 55
Study 18455252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic boost (fSRT) of 20 Gy in 4 fractions
Number of subjects: 25
Study 18455252 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (control)
Number of subjects: 25
Study 16052393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (low molecular weight heparin) administered immediately after cesarean section until mobilization
Number of subjects: 37
Study 16052393 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 women without any other risk factors)
Number of subjects: 37
Study 12480804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single brand of ready-to-eat cereal with 2/3 C skim milk and a 100 Kcal portion of fruit for breakfast and as a replacement for either lunch or dinner for weeks 1 and 2, followed by a Volumetric diet for weeks 3 to 6.
Number of subjects: 106
Study 12480804 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety of ready-to-eat cereals for breakfast and as a replacement for either lunch or dinner for weeks 1 and 2, followed by a Volumetric diet for weeks 3 to 6.
Number of subjects: 106
Study 12480804 — intervention group
Group type: COMPARATOR
Intervention: No dietary instruction during the six-week study.
Number of subjects: 106
Study 12480804 — intervention group
Group type: COMPARATOR
Intervention: No intervention prior to adoption of the Volumetric diet for weeks 3 to 6.
Number of subjects: 106
Study 8746864 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent procedures
Number of subjects: 64
Study 8746864 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug trials conducted by hospitals
Number of subjects: 64
Study 8746864 — intervention group
Group type: EXPERIMENTAL
Intervention: Signed consent form
Number of subjects: 64
Study 8746864 — intervention group
Group type: EXPERIMENTAL
Intervention: Right to withdraw from trial
Number of subjects: 64
Study 1719924 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 0
Study 6185014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortofemoral bypass
Number of subjects: 51
Study 6185014 — intervention group
Group type: COMPARATOR
Intervention: Saphenous bypass
Number of subjects: 51
Study 29943518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Crisis Response Plan (E-CRP)
Number of subjects: 97
Study 29943518 — intervention group
Group type: COMPARATOR
Intervention: Standard Crisis Response Plan (treatment as usual)
Number of subjects: 97
Study 30142573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation of the right dorsolateral prefrontal cortex (preceding reencounter phase)
Number of subjects: 118
Study 30142573 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 118
Study 30142573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation of the right dorsolateral prefrontal cortex (following reencounter phase)
Number of subjects: 118
Study 26364288 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing clopidogrel 75 mg daily (extended‐dual antiplatelet therapy, DAPT, group)
Number of subjects: 1799
Study 26364288 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing clopidogrel (aspirin group)
Number of subjects: 1799
Study 26364288 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing clopidogrel 75 mg daily (extended‐DAPT group)
Number of subjects: 1799
Study 24476775 — intervention group
Group type: EXPERIMENTAL
Intervention: Block periodization training program (BP)
Number of subjects: 24
Study 24476775 — intervention group
Group type: COMPARATOR
Intervention: Traditional periodization program (TP)
Number of subjects: 24
Study 23035060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm ischemic preconditioning (BAIPC), 5 brief cycles of ischemia followed by reperfusion, performed twice daily over 300 days.
Number of subjects: 68
Study 23035060 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated), standard medical management only.
Number of subjects: 68
Study 23035060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm ischemic preconditioning (BAIPC)
Number of subjects: 68
Study 18846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (low dose: 0.12 g/kg for women, 0.14 g/kg for men)
Number of subjects: 32
Study 18846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (high dose: 0.37 g/kg for women, 0.42 g/kg for men)
Number of subjects: 32
Study 18846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 32
Study 18846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 32
Study 18846366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both alcohol and caffeine groups)
Number of subjects: 32
Study 18437797 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 17
Study 18437797 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placed implants
Number of subjects: 17
Study 18437797 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants
Number of subjects: 17
Study 18437797 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 17
Study 15149254 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded visual word naming
Number of subjects: 2428
Study 15149254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical decision performance
Number of subjects: 2428
Study 11586014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product of calcipotriol and betamethasone dipropionate
Number of subjects: 25
Study 11586014 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate
Number of subjects: 25
Study 11586014 — intervention group
Group type: COMPARATOR
Intervention: All treatments except for the vehicle
Number of subjects: 25
Study 11586014 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 25
Study 9676347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release pellets (500 mg theophylline)
Number of subjects: 16
Study 9676347 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion (350 mg theophylline over 8 h)
Number of subjects: 16
Study 7734460 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (once per month non‐random urine screen, counseling session and doctor visit, two times per month methadone pick up, a quarterly true random urine screen, and participation in a diversion control program)
Number of subjects: 130
Study 7734460 — intervention group
Group type: COMPARATOR
Intervention: Control condition (staying under standard conditions for six months and then being transferred to the experimental condition for six months)
Number of subjects: 130
Study 7734460 — intervention group
Group type: EXPERIMENTAL
Intervention: Study of Medical Maintenance (SMM) protocol 1 (once per month random urine screen, extending the experimental condition to two years)
Number of subjects: 130
Study 7734460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot subjects (N = 75)
Number of subjects: 130
Study 2511776 — intervention group
Group type: EXPERIMENTAL
Intervention: Static pulmonary inflation during ECC, PEEP 5-10 cm H2O, F1O2 1.0
Number of subjects: 30
Study 2511776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ventilation during ECC, rate 10/min, PEEP 5 cm H2O, F1O2 1.0
Number of subjects: 30
Study 2511776 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-frequency ventilation during ECC, rate 120/min, PEEP 5 cm H2O, F1O2 1.0
Number of subjects: 30
Study 31997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment with Huoxue Xiaoyi Granule before ovulation and Bushen Zhuyun Granule after ovulation for 6 menstrual cycles.
Number of subjects: 202
Study 31997236 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group receiving placebo treatment for 6 menstrual cycles.
Number of subjects: 202
Study 31997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment.
Number of subjects: 202
Study 31997236 — intervention group
Group type: COMPARATOR
Intervention: Adverse events comparison between groups.
Number of subjects: 202
Study 30940414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 1333
Study 30940414 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 1333
Study 27837268 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (7000 IU/day)
Number of subjects: 58
Study 27837268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25231512 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-280778 10 mg
Number of subjects: 155
Study 25231512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 25231512 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 155
Study 25231512 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (placebo, ACT-280778, amlodipine)
Number of subjects: 155
Study 24168077 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid
Number of subjects: 218
Study 24168077 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 218
Study 24168077 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid (post-hoc subgroup analysis)
Number of subjects: 218
Study 24168077 — intervention group
Group type: COMPARATOR
Intervention: Saline control (post-hoc subgroup analysis)
Number of subjects: 218
Study 22955399 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder hemiarthroplasty
Number of subjects: 32
Study 22955399 — intervention group
Group type: COMPARATOR
Intervention: ORIF with locking plate
Number of subjects: 32
Study 19546359 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly L-AMB dosing (7.5 mg/kg)
Number of subjects: 24
Study 19546359 — intervention group
Group type: EXPERIMENTAL
Intervention: Single L-AMB dose (15 mg/kg)
Number of subjects: 24
Study 19546359 — intervention group
Group type: COMPARATOR
Intervention: Daily L-AMB dosing (1 mg/kg)
Number of subjects: 24
Study 19546359 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infusion-related reactions
Number of subjects: 24
Study 19546359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxicity
Number of subjects: 24
Study 18322594 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72
Study 18322594 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72
Study 18322594 — intervention group
Group type: COMPARATOR
Intervention: Placebo + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72
Study 15635558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 120
Study 15635558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 120
Study 11903083 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 122
Study 11903083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 122
Study 11903083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 122
Study 10371878 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC mouthrinse (0.05% cetylpyridinium chloride)
Number of subjects: 111
Study 10371878 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 111
Study 10371878 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC mouthrinse
Number of subjects: 111
Study 8549061 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion (250 mg)
Number of subjects: 9
Study 8549061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8549061 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion
Number of subjects: 9
Study 8549061 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic caffeine use
Number of subjects: 9
Study 2244841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging of the intracranial optic nerves and chiasm
Number of subjects: 15
Study 2244841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging of the orbital optic nerves
Number of subjects: 15
Study 346138 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 222
Study 346138 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and antrectomy (TVA)
Number of subjects: 222
Study 31279078 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 86
Study 31279078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 31279078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (with Omeprazole)
Number of subjects: 86
Study 31279078 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (with Placebo)
Number of subjects: 86